RHAPSODY, Biomarkers and Novel Clinical Trial design in type 2 diabetes (T2D) and prediabetes
(2021) In Endocrinology, Diabetes and Metabolism 4(2).- Abstract
Developing a novel therapeutic product for the treatment of type 2 diabetes (T2D) is a long, resource-intensive process. Novel biomarkers could potentially aid clinical trial design by shortening clinical trials or enabling better prediction of at-risk populations and/or disease progression. Novel clinical trial designs could lead to reduced costs of development and less burden to patients, due to shorter trial duration, and/or less burdensome assessments.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/89dd3759-5a87-403a-96aa-308079027209
- author
- Adams, Rachel ; Daly, Nicole ; Robertson, Elizabeth and Giordano, Giuseppe N. LU
- organization
- publishing date
- 2021
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- biomarkers, disease progression, novel clinical trial design, prediabetes, type 2 diabetes mellitus
- in
- Endocrinology, Diabetes and Metabolism
- volume
- 4
- issue
- 2
- publisher
- John Wiley & Sons Inc.
- external identifiers
-
- pmid:33855210
- scopus:85097246012
- ISSN
- 2398-9238
- DOI
- 10.1002/edm2.207
- language
- English
- LU publication?
- yes
- id
- 89dd3759-5a87-403a-96aa-308079027209
- date added to LUP
- 2020-12-15 14:45:26
- date last changed
- 2024-03-20 21:53:28
@article{89dd3759-5a87-403a-96aa-308079027209, abstract = {{<p>Developing a novel therapeutic product for the treatment of type 2 diabetes (T2D) is a long, resource-intensive process. Novel biomarkers could potentially aid clinical trial design by shortening clinical trials or enabling better prediction of at-risk populations and/or disease progression. Novel clinical trial designs could lead to reduced costs of development and less burden to patients, due to shorter trial duration, and/or less burdensome assessments.</p>}}, author = {{Adams, Rachel and Daly, Nicole and Robertson, Elizabeth and Giordano, Giuseppe N.}}, issn = {{2398-9238}}, keywords = {{biomarkers; disease progression; novel clinical trial design; prediabetes; type 2 diabetes mellitus}}, language = {{eng}}, number = {{2}}, publisher = {{John Wiley & Sons Inc.}}, series = {{Endocrinology, Diabetes and Metabolism}}, title = {{RHAPSODY, Biomarkers and Novel Clinical Trial design in type 2 diabetes (T2D) and prediabetes}}, url = {{http://dx.doi.org/10.1002/edm2.207}}, doi = {{10.1002/edm2.207}}, volume = {{4}}, year = {{2021}}, }